Review
doi: 10.1016/j.euroneuro.2015.08.019. Epub 2015 Sep 7.A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature
Affiliations
- PMID:26527055
- DOI: 10.1016/j.euroneuro.2015.08.019
Item in Clipboard
Review
A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature
Joseph Zohar et al. Eur Neuropsychopharmacol.2015 Dec.
Display options
Format
Display options
Format
Abstract
Neuroscience based Nomenclature (NbN) is a new system of classifying psychotropic drugs by their pharmacological profile. The NbN was developed to replace the current indication-based nomenclature and to provide an up-to-date and more useful framework to better inform pharmacological decisions. NbN provides updated relevant and specific scientific, regulatory and clinical information, aiming to support rational and lucid prescribing. This pharmacologically driven nomenclature, which highlights pharmacological domains and modes of action, may also increase drug adherence as it clarifies the rationale for selecting a specific psychotropic agent.
Keywords: Adherence; Mode of action; Neuroscience; Nomenclature; Pharmacological domain; Psychotropic drugs.
Copyright © 2015. Published by Elsevier B.V.
Similar articles
- A new nomenclature for classifying psychotropic drugs.Caraci F, Enna SJ, Zohar J, Racagni G, Zalsman G, van den Brink W, Kasper S, Koob GF, Pariante CM, Piazza PV, Yamada K, Spedding M, Drago F.Caraci F, et al.Br J Clin Pharmacol. 2017 Aug;83(8):1614-1616. doi: 10.1111/bcp.13302. Epub 2017 May 24.Br J Clin Pharmacol. 2017.PMID:28401576Free PMC article.
- Neuroscience-based nomenclature (jNbN) to replace traditional terminology of psychotropic medications.Möller HJ, Schmitt A, Falkai P.Möller HJ, et al.Eur Arch Psychiatry Clin Neurosci. 2016 Aug;266(5):385-6. doi: 10.1007/s00406-016-0699-0.Eur Arch Psychiatry Clin Neurosci. 2016.PMID:27216433No abstract available.
- [Newly developed nomenclature (Neuroscience-based Nomenclature)].Uchida H, Yamawaki S.Uchida H, et al.Nihon Shinkei Seishin Yakurigaku Zasshi. 2016 Jun;36(3):69-71.Nihon Shinkei Seishin Yakurigaku Zasshi. 2016.PMID:27506083Japanese.
- A proposed system for classifying psychotropic drugs.Howland RH.Howland RH.J Psychosoc Nurs Ment Health Serv. 2014 Dec 1;52(12):13-5. doi: 10.3928/02793695-20141118-05.J Psychosoc Nurs Ment Health Serv. 2014.PMID:25453506Review.
- Herbal medicine for psychiatric disorders: Psychopharmacology and neuroscience-based nomenclature.Tang SW, Tang WH, Leonard BE.Tang SW, et al.World J Biol Psychiatry. 2019 Oct;20(8):586-604. doi: 10.1080/15622975.2017.1346279. Epub 2017 Jul 11.World J Biol Psychiatry. 2019.PMID:28649903Review.
Cited by
- A Neurodevelopment Approach for a Transitional Model of Early Onset Schizophrenia.De Berardis D, De Filippis S, Masi G, Vicari S, Zuddas A.De Berardis D, et al.Brain Sci. 2021 Feb 23;11(2):275. doi: 10.3390/brainsci11020275.Brain Sci. 2021.PMID:33672396Free PMC article.Review.
- Sex Differences in Depression and Anxiety.Pavlidi P, Kokras N, Dalla C.Pavlidi P, et al.Curr Top Behav Neurosci. 2023;62:103-132. doi: 10.1007/7854_2022_375.Curr Top Behav Neurosci. 2023.PMID:35915385
- The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries.Fugger G, Bartova L, Fabbri C, Fanelli G, Dold M, Swoboda MMM, Kautzky A, Zohar J, Souery D, Mendlewicz J, Montgomery S, Rujescu D, Serretti A, Kasper S.Fugger G, et al.Eur Arch Psychiatry Clin Neurosci. 2022 Jun;272(4):715-727. doi: 10.1007/s00406-021-01368-3. Epub 2022 Jan 6.Eur Arch Psychiatry Clin Neurosci. 2022.PMID:34989830Free PMC article.
- What do patients learn about psychotropic medications on the web? A natural language processing study.Hart KL, Perlis RH, McCoy TH Jr.Hart KL, et al.J Affect Disord. 2020 Jan 1;260:366-371. doi: 10.1016/j.jad.2019.09.043. Epub 2019 Sep 10.J Affect Disord. 2020.PMID:31539672Free PMC article.
- The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?Lippi M, Fanelli G, Fabbri C, De Ronchi D, Serretti A.Lippi M, et al.Int Clin Psychopharmacol. 2022 Nov 1;37(6):263-275. doi: 10.1097/YIC.0000000000000417. Epub 2022 Jul 12.Int Clin Psychopharmacol. 2022.PMID:35815937Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous